Nicholas Wealth LLC. Takes $1.33 Million Position in Merck & Co., Inc. $MRK

Nicholas Wealth LLC. purchased a new position in Merck & Co., Inc. (NYSE:MRK) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,045 shares of the company’s stock, valued at approximately $1,329,000. Merck & Co., Inc. makes up about 0.9% of Nicholas Wealth LLC.’s investment portfolio, making the stock its 27th biggest holding.

Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $3,997,933,000. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after buying an additional 11,156,354 shares during the period. DLD Asset Management LP boosted its stake in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after buying an additional 11,000,000 shares during the period. Cardano Risk Management B.V. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $1,012,530,000. Finally, Jennison Associates LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $585,192,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $128.35 on Friday. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $128.78. The business has a 50-day moving average of $116.08 and a two-hundred day moving average of $114.33. The stock has a market capitalization of $316.99 billion, a P/E ratio of 36.15, a P/E/G ratio of 2.89 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the firm posted $2.22 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Analysts Set New Price Targets

MRK has been the subject of several research reports. JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $128.72.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.